Rizatriptan

Rizatriptan

Clinical data
Trade names	Maxalt
AHFS/Drugs.com	Monograph
MedlinePlus	a601109
Pregnancy category	C
Routes of administration	Oral
ATC code	N02CC04 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	45%
Protein binding	14%
Metabolism	by monoamine oxidase
Elimination half-life	2–3 hours
Excretion	82% urine; 12% faeces
Identifiers
IUPAC name N,N-dimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine
CAS Number	145202-66-0
PubChem CID	5078
IUPHAR/BPS	51
DrugBank	APRD00008 Y
ChemSpider	4900 Y
UNII	WR978S7QHH
KEGG	D00675 N
ChEBI	CHEBI:48273 N
ChEMBL	ChEMBL905 Y
CompTox Dashboard (EPA)	DTXSID2023565
ECHA InfoCard	100.243.719
Chemical and physical data
Formula	C15H19N5
Molar mass	269.345 g/mol g·mol−1
3D model (JSmol)	Interactive image
SMILES n1cn(nc1)Cc2cc3c(cc2)ncc3CCN(C)C
InChI InChI=1S/C15H19N5/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3 Y Key:ULFRLSNUDGIQQP-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Rizatriptan (Maxalt) is a 5-HT1 agonist triptan drug developed by Merck & Co. for the treatment of migraine headaches. It is available in strengths of 5 and 10 mg as tablets and orally disintegrating tablets (Maxalt-MLT).

Maxalt obtained approval by the United States Food and Drug Administration (FDA) on June 29, 1998. It is a second-generation triptan.

Rizatriptan is available only by prescription in the United States, Canada and New Zealand. Similarly, it is classed as a POM (Prescription Only Medicine) in the United Kingdom, Italy (as Rizaliv), Israel (as Rizalt), The Netherlands (as Maxalt), Croatia (as Maxalt) and Spain (as Maxalt)

Use

Rizatriptan is used to treat acute migraine attacks. It does not prevent future migraine attacks.

Indications

• migraine headache with or without aura

Contraindications

• coronary artery disease
• use of monoamine oxidase inhibitors

Adverse effects

Severe:

• coronary artery vasospasm
• transient myocardial ischemia
• myocardial infarction
• ventricular tachycardia
• ventricular fibrillation
• hypertensive crisis

Atypical sensations:

• paresthesia

Cardiovascular:

• palpitations
• syncope
• hypertension
• hypotension

Ear, nose, and throat:

• tinnitus
• sinusitis
• allergic rhinitis
• upper respiratory tract inflammation

Gastrointestinal:

• diarrhea

Muscular:

• myalgia

Neurological:

• phonophobia
• photophobia

Respiratory:

• dyspnea

Skin:

• sweating

Miscellaneous:

• hypersensitivity

External links

• Maxalt website by Merck & Co.